The Promising Pathway Act is a commonsense step to give the FDA the flexibility it needs to serve Americans with these most trying diseases.

The time is not the right amount of time, and the children are being ignored in this and it shouldn't be that way.

However, millions of Americans with these diseases still lack any FDA approved treatments.

Mr. President, I call up my amendment No. 1182 and ask that it be reported by number. The PRESIDING OFFICER. The clerk will report. The senior assistant legislative clerk read as follows: The Senator from Indiana [Mr. Braun], for himself…

Thank you, Mr.

However, millions of Americans with these diseases still lack any FDA approved treatments.

The Promising Pathway Act is a commonsense step to give the FDA the flexibility it needs to serve Americans with these most trying diseases.

We should be that leading edge and we should have a system that accommodates it.

That is why we need the formality of PPA.

The time is not the right amount of time, and the children are being ignored in this and it shouldn't be that way.

I have been working on this for most of the five-years I have been here in the Senate.

My simple answer is that ALS patients are willing to accept greater risk because we know what is behind door number two.

Patients deserve a promising pathway at the FDA.

This is long overdue.

This is long overdue.

The fact that we haven't done that in 20-some years makes this very much an academic discussion.

We borrow now 30 cents on every dollar we spend.

I have no question that those policies would be much more costly than any reasonable benefits we'd get in any other area, including climate policy.